Pemafibrate racemate is primarily used in the treatment of dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. It works by activating peroxisome proliferator-activated receptor alpha (PPARα), which helps in reducing triglycerides and increasing high-density lipoprotein (HDL) cholesterol levels. This makes it effective in managing cardiovascular risks associated with lipid abnormalities. Additionally, it is being studied for its potential benefits in non-alcoholic fatty liver disease (NAFLD) due to its lipid-lowering and anti-inflammatory properties. Its application is particularly relevant for patients who do not respond adequately to conventional lipid-lowering therapies.